Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the appointments of David Bryant and
Avacta Group PLC (AIM:AVCT) Update on timing of preliminary results
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces that the preliminary results for
Avacta Group PLC (AIM:AVCT) Notice of Results
Investor Presentation via Investor Meet Company
Avacta Group PLC (AIM:AVCT) Investor Webinar on 15 May 2025 at 6.00 pm (BST).
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that Dr Christina
Avacta Group Plc (AIM:AVCT) A Company Developing Next-Generation Cancer Therapies
Avacta Group plc (AVCT) is a life sciences company developing next-generation cancer therapies that deliver powerful anti-tumour payloads directly to the tumour site.
Avacta Group PLC – Avacta presents preclinical data at AACR
Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting FAP-EXd (AVA6103) demonstrates tumor growth inhibition and durable complete responses in multiple therapy-resistant preclinical
Avacta Group PLC ((AIM:AVCT) First Quarter of 2025 Outlining Progress Against Strategic Objectives
AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter
Avacta Group PLC (AIM:AVCT) Avacta Announces Presentations at AACR
Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
Avacta Group PLC (AIM:AVCT) Avacta to Present at Leerink Healthcare Conference
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
Avacta Group PLC (AIM:AVCT) Agreement to Sell Launch Diagnostics and a Corporate Update
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, announces that it has agreed to sell
Avacta Group PLC (AIM:AVCT) Avacta Announces Data from AVA6000 Phase 1 trial
Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers
Avacta Group PLC (AIM:AVCT) Appoints Brian Hahn as Chief Financial Officer
Brian brings 25 years’ senior financial and operational experience, including leading GlycoMimetics’ Nasdaq IPO and financial operations